Relapsed or very aggressive high-grade NHL and refractory low-grade NHL have a poor clinical outcome. Autologous BMT may be used but is of limited efficacy in these cases. Allogeneic BMT offers the advantage of tumour-free bone marrow and a possible GVL effect. Between 1987 and 1996, 13 patients (median age 31 years) suffering from lymphoid malignancies underwent allo-BMT. Four patients had low-grade NHL, three intermediate-grade and six high-grade NHL. Three patients were grafted with evolutive disease, four were in partial remission after several courses of chemotherapy, two were in CR2 and four were in CR1 after initial therapy. The mean number of prior treatments was 2.7 (1-6). Median time from diagnosis to BMT was 25 months (4-90). The conditioning regimen consisted of cyclophosphamide (120 mg/kg/day for all, plus VP16 in one case) and total body irradiation. Five out of the seven patients who were not in CR at the time of transplantation entered CR after BMT. Eight patients developed acute GVHD gradeуII and four had chronic GVHD. Nine patients are alive, eight in CR with a median follow-up of 49.8 months post BMT (2-125). Overall survival is 67.3% and the median time for EFS is 102 months. Two patients with low-grade NHL relapsed 61 and 102 months post BMT and were treated with DLI. One patient with a stage IV SLL had a partial remission and one with multiple cutaneous localisation of FL entered CR after grade IV acute GVHD. Allo-BMT is a highly effective treatment for advanced poor prognosis lymphoid malignancies with acceptable toxicity. Moreover, DLI can be effective in relapsing patients. Keywords: alloBMT; non-Hodgkin's lymphoma; donor lymphocyte infusion Despite the development of new strategies producing high rates of complete remission, the majority of patients with low-grade non-Hodgkin's lymphoma (NHL) and at least
half of patients with intermediate or high-grade lymphoma will experience relapse. [1] [2] [3] Salvage chemotherapy is usually effective in inducing second remission but the probability of cure is very low. 4 High-dose therapy with autologous stem cell transplantation (ASCT) is effective in chemosensitive relapsed patients and may prolong survival. 5, 6 Status at transplantation is probably a major prognostic factor since autologous BMT is of limited efficacy in refractory or partially responding patients. 5, 7, 8 Recurrences post autologous BMT allow limited options and most patients die of progressive disease.
Allogeneic BMT is an alternative approach for the treatment of initially aggressive, relapsing or refractory NHL. This procedure is restricted to patients with a histocompatible sibling donor and is limited because of toxicity and morbidity due to graft-versus-host disease (GVHD). However, allogeneic BMT avoids the reinfusion of malignant cells and evidence of a graft-versus-lymphoma (GVL) effect limits risk of relapse. 9 Several reports of allogeneic BMT in the treatment of poor prognosis NHL have been published in the last decade but real efficacy and toxicity remain controversial. [10] [11] [12] [13] [14] [15] Nevertheless, some cases of longterm survival have been reported even in patients relapsing after autologous BMT or in refractory patients. 16, 17 We review our data on 13 patients suffering from aggressive or refractory NHL who underwent allogeneic BMT in the same institution.
Patients and methods

Patients
From September 1987 to November 1996 we performed 13 allogeneic BMTs in adults suffering from lymphoid malignancies. All patients presented with poor prognosis disease based on refractory or recurrent disease after frontline therapy or were poor prognosis according to the international prognosis index (IPI). Patient characteristics are summarised in Table 1 . There were nine males and four females with a median age of 31.5 years (range Twelve patients had disseminated disease stage IV and one had a stage II bulky mediastinal mass lymphoblastic lymphoma.
At the time of BMT four patients were in first complete remission (CR1) after chemotherapy for lymphoblastic lymphoma. Two patients were in second complete remission (CR2): one (case 1) had relapsed 31 months after autologous BMT with a stage IV high-grade lymphoma with pulmonary and liver localisation and was still chemosensitive to an ESAP (etoposide, cisplatyl, adriamycine, prednisone) regimen, and the other (case 3) relapsed 30 months after intensive chemotherapy for a Burkitt lymphoma with pleural and central nervous system localisation. Four patients were in partial remission (PR) after several courses of chemotherapy and three patients were grafted with evolving disease. One patient (case 5) with a stage IV small lymphocytic lymphoma relapsed 84 months after initial diagnosis and did not respond to an intensive chemotherapy regimen containing anthracycline. Twelve patients had HLA-identical sibling donors and one an HLAidentical unrelated donor.
Supportive care
Infection prophylaxis included oral antifungal therapy with fluconazole and intravenous vancomycin from day 0 to day 30. Each patient underwent oral gut decontamination with oral colimycine and received a sterile diet. All patients received irradiated and CMV-negative blood products. All but one patient (case 12) received no haematopoietic growth factors.
Post-transplant evaluation
Toxicity: Clinical and biological toxicity were evaluated according to the WHO criteria. GVHD was assessed and scored using standard criteria.
Efficacy: Patients were monitored twice a week from day 40 to day 100 and every 3 months until day 365, and triannually thereafter. Response to therapy was assessed by physical examination, blood count, bone marrow biopsy, and CT scan of thorax and abdomen.
Study definitions and statistical analysis
Complete remission was defined as the disappearance of all disease and symptoms related to lymphoma, and partial remission was defined as more than 50% reduction in the sum of products of the two greatest perpendicular diameters of all areas of known disease.
Univariate analysis was performed to assess overall survival and event-free survival (EFS) using the Kaplan-Meier method (SPSS 7.0 software).
Results
Assessment of toxicity
All patients were evaluable for acute toxicity. There were no toxic deaths during hospitalisation. The data are summarised in Table 2 .
Haematological toxicity: All patients achieved successful engraftment. The mean duration of neutropenia (neutrophil Ͻ0.5 × 10 9 /l) and thrombocytopenia (platelets Ͻ50 × 10 9 /l) was 18.8 days (range 5-41 days) and 36.7 days (range 9-125 days), respectively. The mean number of red blood cells (RBC) and platelet unit transfusions was 6.5 ± 4 and 5.5 ± 3, respectively. Patient 12 became progressively refractory to platelet transfusions and developed severe grade IV GVHD. He died at day 60 of cerebral haemorrhage. GVHD = graft-versus-host disease; GD = grade; DLI = donor lymphocytes infusion; NE = not evaluable. Infections: From day 0 to day 28, while the patients were neutropenic, we observed six severe bacterial infections with favourable outcome after antibiotic therapy. One patient died of extensive aspergillosis 7 months post BMT in the context of GVHD.
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GVHD: Acute GVHD was observed in 9 cases: grade I n = 1, grade II n = 5, grade III n = 2 and grade IV n = 1. Two patients developed extensive chronic skin GVHD. All were treated successfully with steroids except patient 12 who died from refractory thrombocytopenia in the context of extensive GVHD. This was the only patient who had undergone unrelated donor BMT. Two others had chronic GVHD: one died 7 months post transplant because of aspergillosis and hepatic failure.
Response and follow-up
All but one patient (case 12) were evaluable for tumour response. Five out of the seven partial responders or patients refractory at the time of transplant entered complete remission. In cases 2 and 8, no residual marrow disease could be detected using PCR or flow cytometry. Patient 5, who was grafted for refractory small lymphocytic lymphoma (SLL), showed disease progression after haematological recovery and died 7 months after BMT of Richter's syndrome. Eight patients (62%) were still in CR from 15 to 111 months following BMT. One of these (case 13) committed suicide 30 months after BMT. With a median follow-up of 49.8 months overall survival is 67.3% and the median time for event-free survival is 102 months (Figure 1) .
Late relapse
Two patients with low-grade lymphoma (SLL and FL) relapsed 61 and 102 months post BMT, respectively. Patient 2 presented with polyadenopathy and peripheral CD5 + /CD19 + lymphocytosis (38 × 10 9 /l). Patient 9 had a recurrent follicular lymphoma with multiple subcutaneous lesions. They were both treated with initial donor lymphocyte infusion (DLI): 4 × 10 8 and 4.7 × 10 8 cells/kg were reinfused to patients 2 and 9 respectively, without GVHD prophylaxis. The SLL patient developed acute grade II GVHD followed by skin and pulmonary symptoms of chronic GVHD. We observed a partial, transient remission with a decrease in the number of B CD5 + cells ( Figure  2 ). Patient 9 developed grade IV GVHD with a favourable outcome after steroids and CYA: she achieved CR without any symptoms of chronic GVHD, with a follow-up of 24 months.
Discussion
We report the results of 13 patients who underwent allogeneic BMT from 1987 to 1996. All patients were referred for BMT because of poor prognosis NHL. Seven were either refractory or partial responders to frontline therapy, two were in CR2, and four had aggressive high-grade NHL with a grade 3 international prognosis index (IPI). 18 In such cases, it is well known that cure and long-term survival are rarely observed.
Refractory or relapsing patients with high-grade or intermediate-grade NHL after frontline therapy have an estimated long-term survival of less than 10%. High-dose therapy with autologous stem cell transplantation has been proposed to improve the outcome of these patients. Disease status at the time of BMT is decisive for response to intensive therapy. For relapsing NHL in patients who are still chemosensitive, several studies have demonstrated the efficacy of ASCT as a salvage therapy, with a progressionfree survival of 48% and EFS of 46%. 5, 6 For refractory NHL, the efficacy of ASCT is very limited with less than 25% progression-free patients at 4 years. 5 This procedure does not improve the outcome of partial responders after frontline therapy. 8 Thus, for all these poor prognosis NHL patients, it is reasonable to investigate other strategies.
Several studies have been published on the feasibility and efficacy of allogeneic BMT in the treatment of NHL. [10] [11] [12] [13] [14] [15] [19] [20] However, the results are controversial and the indications require clarification. In the Ratanatharathorn study, 13 comparing autologous and allogeneic BMT, no difference was noted in progression-free survival rate with a median follow-up of 14 months. The main factor that affected EFS was the status of disease at the time of transplant. However, this study confirmed the existence of a graftversus-lymphoma effect which was first suggested by Jones et al, 9 who showed that the probability of relapse was significantly lower for patients who underwent allogeneic BMT than for autotransplanted patients.
In our study, we performed allogeneic BMT in 13 patients suffering from recurrent and refractory NHL after frontline therapy or very aggressive high-grade NHL at the time of initial diagnosis. All but one underwent allogeneic BMT from an identical sibling donor. Toxicity was acceptable. We observed only one toxic death in the case of the patient grafted from an unrelated donor. Eight patients had acute grade I to III GVHD with favourable outcome after steroid therapy. At the time of transplant, six patients were in CR: five out of the seven remaining patients entered CR. With a median follow-up of 49.8 months, overall survival is 67.3% and the median time for EFS is 102 months, which compares favourably with previous studies. In one patient, allogeneic BMT was performed after relapse post-autologous BMT and the duration of CR2 is now longer than CR1. This observation confirms the GVL effect and the possibility of salvage therapy after lymphoma recurrence postautologous BMT. 16, 17 Our study confirms that long-term duration of CR may occur in very poor prognosis NHL after allogeneic BMT.
Management of patients relapsing after allogeneic BMT is not yet defined. In one study, four out of nine patients responded after stopping CYA or tacrolimus: two of these re-entered CR. 21 For late relapses, DLI may be offered but efficacy remains controversial. In Van Besien's study, 21 there was no response among three patients. Two cases of relapsed CLL entering CR post DLI have been reported. 22, 23 We gave DLI to two relapsing patients and the patient with a follicular lymphoma re-entered CR and is still in CR after 24 months. In the other case, we observed a transient significant decline in the number of B CD5 cells. Our study confirms that graft-versus-lymphoma effect may be induced by immunological therapy in low-grade lymphoma.
This study emphasises the feasibility and the efficacy of allogeneic BMT for young patients suffering from poor prognosis NHL. For such patients with HLA-identical sibling donors, allogeneic BMT offers the best results with a possibility of long-term survival associated with acceptable morbidity. The role of DLI in cases of lymphoma recurrence after allogeneic BMT needs to be clearly defined in prospective studies.
